Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 17/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 15/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4466578 | 0.82 | TRPV4 (0.43) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL3026622 | 0.78 | MAOB (0.42) | TRPV4 | |
| SCHEMBL30919072 | 0.76 | TRPV4 (0.61) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL18297999 | 0.76 | CYP11B2 (0.67) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL57346 | 0.76 | TRPV4 (0.61) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL1797379 | 0.74 | TRPV4 (0.59) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL9612021 | 0.74 | CYP11B2 (0.68) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL362787 | 0.73 | TRPV4 (1.00) | TRPV4CYP11B2CYP11B1DAO | |
| SCHEMBL518867 | 0.73 | TRPV4 (0.57) | TRPV4CYP11B2 | |
| SCHEMBL1156401 | 0.73 | TRPV4 (0.57) | TRPV4CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517992-B2 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2009-04-14 | — | — | US | disclosed |
| EP-1534276-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2006-07-27 | — | — | US | disclosed |
| EP-1534276-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004021969-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR2H, POLR2E, POLR1E | TRPV4 4872/4885CYP11B2 3176/4885CYP11B1 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.